» Articles » PMID: 2114950

Inhibition of Thymidylate Synthase by the Diastereoisomers of Leucovorin

Overview
Specialty Oncology
Date 1990 Jan 1
PMID 2114950
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

The clinical formulation of leucovorin (5-CHO-FH4) is a mixture of diastereoisomers with markedly different pharmacologic properties. Comparatively little information is available concerning the cellular pharmacology of reduced folate stereoisomers, due largely to the difficulty in preparing sufficient quantities of these compounds for in vitro use. Recent improvements in HPLC technology have now facilitated this process, enabling studies of folate stereochemistry on a larger scale. Using purified (6R) and (6S) leucovorin, we examined the effects of these compounds on the enzymatic activity of Lactobacillus casei thymidylate synthase (TS) in a cell-free system. The natural (6S), unnatural (6R), and racemic (6R,S) leucovorin preparations inhibited TS activity by 50% at concentrations of 0.11, 2.1, and 0.52 mM, respectively. Dixon plots demonstrated the inhibition to be competitive, with Ki values of 85 microM, 1.59 mM, and 385 microM for (6S), (6R), and (6R,S) leucovorin, respectively. In view of the high doses of leucovorin given clinically and the slow clearance of the unnatural isomer, our observations suggest that leucovorin may have important direct inhibitory effects on folate-requiring enzymes.

Citing Articles

Protective effect of miR-18a in resected liver metastases of colorectal cancer and FOLFOX treatment.

Franz C, Jotten L, Wuhrl M, Hartmann S, Klupp F, Schmidt T Cancer Rep (Hoboken). 2023; 6(12):e1899.

PMID: 37698257 PMC: 10728504. DOI: 10.1002/cnr2.1899.


Relationship between folate concentration and expression of folate-associated genes in tissue and plasma after intraoperative administration of leucovorin in patients with colorectal cancer.

Taflin H, Odin E, Derwinger K, Carlsson G, Gustavsson B, Wettergren Y Cancer Chemother Pharmacol. 2018; 82(6):987-997.

PMID: 30269276 PMC: 6267663. DOI: 10.1007/s00280-018-3690-9.


A phase II and pharmacokinetic study of 6S-leucovorin plus 5-fluorouracil in patient with colorectal carcinoma.

Meropol N, Petrelli N, Rustum Y, Rodriguez-Bigas M, Blumenson L, Frank C Invest New Drugs. 1995; 13(2):149-55.

PMID: 8617578 DOI: 10.1007/BF00872864.


Five-day infusional fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alpha-2b: a phase I study.

Vokes E, OBrien S, Vogelzang N, Schilsky R, Ratain M Cancer Chemother Pharmacol. 1993; 32(5):347-52.

PMID: 8339384 DOI: 10.1007/BF00735917.


Pharmacokinetics of rac-leucovorin vs [S]-leucovorin in patients with advanced gastrointestinal cancer.

Mader R, Steger G, Rizovski B, Sieder A, Locker G, Gnant M Br J Clin Pharmacol. 1994; 37(3):243-8.

PMID: 8198932 PMC: 1364754. DOI: 10.1111/j.1365-2125.1994.tb04270.x.


References
1.
Banerjee C, BENNETT Jr L, BROCKMAN R, Sani B, TEMPLE Jr C . A convenient procedure for purification of thymidylate synthase from L1210 cells. Anal Biochem. 1982; 121(2):275-80. DOI: 10.1016/0003-2697(82)90479-1. View

2.
Wahba A, FRIEDKIN M . Direct spectrophotometric evidence for the oxidation of tetrahydrofolate during the enzymatic synthesis of thymidylate. J Biol Chem. 1961; 236:PC11-2. View

3.
Galivan J, MALEY G, Maley F . Factors affecting substrate binding in Lactobacillus casei thymidylate synthetase as studied by equilibrium dialysis. Biochemistry. 1976; 15(2):356-62. DOI: 10.1021/bi00647a018. View

4.
FRIEDKIN M, Plante L, CRAWFORD E, Crumm M . Inhibition of thymidylate synthetase and dihydrofolate reductase by naturally occurring oligoglutamate derivatives of folic acid. J Biol Chem. 1975; 250(14):5614-21. View

5.
Choi K, Schilsky R . Resolution of the stereoisomers of leucovorin and 5-methyltetrahydrofolate by chiral high-performance liquid chromatography. Anal Biochem. 1988; 168(2):398-404. DOI: 10.1016/0003-2697(88)90335-1. View